Navigation Links
12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system)

ts. The highest percentage of discontinuations were due to withdrawn consent or lost to follow-up (12 percent and 11 percent, respectively).

The most commonly reported treatment-emergent adverse events reported throughout the study (.10 percent) included decreased appetite, headache, upper respiratory tract infection, cough, pyrexia and decreased weight. Most (98 percent) adverse events were mild or moderate in severity and consistent with known effects of methylphenidate. Three serious adverse events were reported and all were considered unrelated to DAYTRANA use.

DAYTRANA Demonstrated Significant Improvements in ADHD-RS-IV, CGI-I and PGA Scores

In the study, the children experienced a significant overall mean reduction in their ADHD Rating Scale-IV (ADHD-RS-IV) total score. When the study began, the mean total score on the ADHD-RS-IV was 25.0. When using Daytrana, the mean ADHD-RS-IV total scores declined, with children averaging 15.4 at study end. The overall mean change in ADHD-RS-IV total score from study start to end was -9.3 (+/- 16.29) and was statistically significant (P<.0001). The total scores also declined significantly from study start to end on both the inattentiveness and hyperactivity/impulsivity ADHD-RS-IV subscales (P<.0001).

Investigators evaluated DAYTRANA's overall effectiveness using the Clinical Global Impressions-Improvement (CGI-I) and Parent Global Assessment (PGA) scales, both of which yielded significant ratings of improvement at study end, with 83 and 78 percent, respectively, reporting DAYTRANA "very much improved" or "much improved" the children's ADHD symptoms (P<.0001).

The study was supported by funding from Shire.

About ADHD

Approximately 7.8 percent of all school-age children, or about 4.4 million U.S. children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the U.S. Centers for Disease Control and Prevention (CDC). ADHD is one of the mos
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:3/31/2015)... , Mar. 27, 2015 Research and ... the addition of the "European Laboratory Information ... System), by Type (Clinical Pathology Laboratory Information System, ... 2019" report to their offering. ... to grow at a CAGR of 7.6% from ...
(Date:3/31/2015)... N.J. , March 31, 2015  PAION, ... today announced the initiation of a U.S. Phase ... for procedural sedation in patients undergoing colonoscopy. ... faster onset of sedation and greater procedural success ... profile and patients experienced rapid recovery from sedation ...
(Date:3/30/2015)... , 31 mars 2015  Une équipe de scientifiques ... atomique d,un récepteur de surface cellulaire qui ... de thromboses. Contre toute attente, cette recherche ... caractéristiques structurelles qui remettent en cause les ... les récepteurs couplés aux protéines G (RCPG) ...
Breaking Medicine Technology:European Laboratory Information System Market Report 2015: Germany holds a larger share of the laboratory information systems market 2European Laboratory Information System Market Report 2015: Germany holds a larger share of the laboratory information systems market 3PAION Announces Initiation of U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy 2PAION Announces Initiation of U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy 3PAION Announces Initiation of U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy 4De nouvelles structures moléculaires remettent en cause les idées conventionnelles concernant l'action des médicaments sur les récepteurs 2De nouvelles structures moléculaires remettent en cause les idées conventionnelles concernant l'action des médicaments sur les récepteurs 3
... ,, BETHESDA, Md. , June 30 ... an innovator in biotechnology for therapy in diabetes, ... and regulatory consulting services to food, supplement, biotechnology ... subsidiary, Biospherics Incorporated, has signed a license agreement ...
... 30 Xoft, the leading provider of FDA-cleared ... Center of Hoag Memorial Hospital Presbyterian in Newport ... Brachytherapy, eBx™ System to support the launch of its ... progressive, comprehensive approach to breast cancer treatment. The first ...
Cached Medicine Technology:Biospherics Acquires Global Patent Rights from University of Kentucky Research Foundation to Develop Tagatose as a Trigylcerides Therapy 2Biospherics Acquires Global Patent Rights from University of Kentucky Research Foundation to Develop Tagatose as a Trigylcerides Therapy 3Biospherics Acquires Global Patent Rights from University of Kentucky Research Foundation to Develop Tagatose as a Trigylcerides Therapy 4Biospherics Acquires Global Patent Rights from University of Kentucky Research Foundation to Develop Tagatose as a Trigylcerides Therapy 5Hoag Breast Care Center Installs Xoft Electronic Brachytherapy System for IORT Program 2Hoag Breast Care Center Installs Xoft Electronic Brachytherapy System for IORT Program 3Hoag Breast Care Center Installs Xoft Electronic Brachytherapy System for IORT Program 4
(Date:3/31/2015)... (PRWEB) March 31, 2015 Horizon Blue ... today that its efforts to combat health insurance fraud ... a combination of monies recovered and losses avoided -- ... total since Horizon BCBSNJ created its fraud fighting, Special ... BCBSNJ’s anti-fraud efforts have saved members $261 million. ...
(Date:3/31/2015)... An individual’s meniscus (cushion in the knee) ... leg providing stability, load bearing and preservation of the ... Day meeting of the American Orthopaedic Society for Sports ... the potential for biologic healing following a meniscus tear. ... of meniscus tears when a root repair is performed ...
(Date:3/31/2015)... 2015 Burns Engineering announces 3-Day Quick Ship ... the Food & Beverage, Pharmaceutical and Biotech markets. These field ... compliant and are now available as part of Burns’ Quick ... The S01 and S03 with 1/8” and 1/4” ... connections used in process lines 1/4” and larger. Sensors ...
(Date:3/31/2015)... The report “Coagulation/Hemostasis Analyzer Market By ... (APTT, Prothrombin Time/INR, D-Dimer, Fibrinogen), Technology (Mechanical, Optical), ... and studies the major market drivers, restraints, opportunities ... the Rest of the world (RoW). , ... reach $3.58 billion by 2019 from $2.4 billion ...
(Date:3/31/2015)... March 31, 2015 DentalXChange, ... specializes in providing online solutions to connect ... it has achieved full accreditation for the ... Accreditation Program (HNAP) from the Electronic Healthcare ... HNAP accreditation runs in two-year increments and ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Saves Members, Health System a Record $45.4 Million through Anti-fraud Efforts 2Health News:New Way to Evaluate Meniscus Tear Outcomes 2Health News:Burns Engineering Now Offers 3-Day Quick Ship on Sanitary RTDs and Thermocouples 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 3Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 4Health News:DentalXChange Achieves EHNAC Healthcare Network Accreditation for Fifth Consecutive Time 2Health News:DentalXChange Achieves EHNAC Healthcare Network Accreditation for Fifth Consecutive Time 3
... HealthDay Reporter , MONDAY, Dec. 12 (HealthDay News) -- Toddlers ... finding that researchers say may provide a clue to the ... is largely an involuntary process that helps keep the eyes ... are closed, you are temporarily blinded. And throughout a typical ...
... infrastructure, inefficient distribution channels and disruptive black markets must ... with the growing problem of malaria, according to a ... Systems and Management . Historically, malaria is humanity,s ... some regions it remains the biggest infectious threat in ...
... , MONDAY, Dec. 12 (HealthDay News) -- Acupuncture may ... according to a new study. Cancer drugs called ... nerves, especially in the calves and feet, resulting in ... is no effective treatment for the condition, called chemotherapy ...
... Reporter , MONDAY, Dec. 12 (HealthDay News) -- When she was ... Madeline Mann was the world,s smallest surviving baby. At the ... world,s tiniest infant, weighing in at 0.57 pounds. She was one ... the neonatal intensive care unit at Loyola University Medical Center in ...
... Reinberg HealthDay Reporter , MONDAY, Dec. 12 ... colon, breast, prostate and cervical cancer even though guidelines ... finds. As the population of the United States ... will be a continuing battle, experts say. "In an ...
... Patients who receive a blood ... to treat leukemia and other blood diseases are more likely ... disease, a condition caused by the donor cells attacking the ... a donor,s bone marrow, rather than from blood stem cells ...
Cached Medicine News:Health News:Blink Patterns May Be a Window Into Autistic Mind 2Health News:Blink Patterns May Be a Window Into Autistic Mind 3Health News:A logistics approach to malaria in Africa 2Health News:Acupuncture Might Ease Chemotherapy Pain 2Health News:World's Tiniest 'Preemies' Growing Up Healthy: Report 2Health News:World's Tiniest 'Preemies' Growing Up Healthy: Report 3Health News:Are Too Many Older People Screened for Cancer? 2Health News:Are Too Many Older People Screened for Cancer? 3Health News:Bone marrow and blood stem cell transplant survival rates equal, when donor is unrelated to patient 2
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Elmed BC 50 M/M is an all purpose bipolar coagulator with a macro and micro mode. In the micro mode, the unit is ideally suitable for wet-field coagulation in ophthalmology, neurosurgery and other mi...
...
...
Medicine Products: